Quantcast

Latest Human Genome Sciences Stories

2009-04-29 15:05:00

- First HGS product sales achieved with delivery of ABthrax(TM) to U.S.

2009-04-25 09:00:00

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events across the two Phase 3 trials, versus peginterferon alfa-2a - - Submission of global marketing applications planned in fall 2009 - ROCKVILLE, Md., April 25 /PRNewswire-FirstCall/ --...

2009-04-22 15:00:00

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2009.

2009-03-27 07:00:00

ROCKVILLE, Md., March 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the 4th Annual Citi Biotech Day will be webcast and may be accessed at www.hgsi.com.

2009-03-25 06:16:00

ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-03-17 14:38:00

WASHINGTON, March 17 /PRNewswire/ -- The 3rd Annual Walk for Lupus Now Washington will occur on Saturday, April 18 from 9:00 a.m. to 12:00 noon on Pennsylvania Avenue, N.W. between 13th and 3rd Streets.

2009-03-13 07:00:00

ROCKVILLE, Md., March 13 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-03-09 06:01:00

ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-03-09 06:00:00

- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events versus peginterferon alfa-2a - - Filing of global marketing applications planned in fall 2009 - ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome...

2009-02-26 15:11:00

- Positive results for first Albuferon(R) Phase 3 trial announced in December 2008; data from second trial expected March 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes initiated by GlaxoSmithKline (GSK) - - $106 million of convertible debt repurchased for $50 million in cash - - 2009 revenue expected to grow to $250 million; at least $150 million from delivery of ABthrax(TM) to Strategic National Stockpile - ROCKVILLE, Md., Feb.


Word of the Day
bretelles
  • In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.
The word 'bretelles' comes from a French word meaning 'braces'.